Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The U.S. FDA issued a Form 483 with five observations
The medicine was well tolerated, with no unexpected safety issue
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Subscribe To Our Newsletter & Stay Updated